Rovetini Luca, Belciug Gianina Florentina, Massai Luisa, Nonne Francesca, Alfini Renzo, Ranchod Heena, Reddy Denasha L, Molfetta Mariagrazia, Oldrini Davide, Totsika Makrina, Iturriza Miren, Dangor Ziyaad, Giannelli Carlo, Madhi Shabir A, Micoli Francesca, Carducci Martina, Rossi Omar
GSK Vaccines Institute for Global Health (GVGH), GSK Global Health Vaccines R&D, Via Fiorentina 1, 53100 Siena, Italy.
WITS Vaccines and Infectious Diseases Analytics Unit, South African Medical Research Council, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa.
Methods Protoc. 2025 May 19;8(3):52. doi: 10.3390/mps8030052.
is a leading cause of nosocomial infections, neonatal sepsis, and childhood mortality worldwide. A drastic rise in antibiotic-resistant isolates poses an urgent threat to humanity, and the World Health Organization (WHO) has classified this as a critical-priority antimicrobial-resistant (AMR) pathogen. Recent advancements in developing vaccines against have highlighted the lack of standardized assays to evaluate immunogenicity, complicating comparison among different vaccines under development and the establishment of a serological threshold of risk reduction (SToRR). Here, we describe the development of a ten-plex multiplex assay to measure IgG against capsular polysaccharides (K2, K25, K102, K149), O antigens (O1v1, O1v2, O2v1, O2v2 and O5), and a conserved protein (MrkA). A standard curve was established by pooling human sera from naturally exposed subjects and then calibrated in terms of Relative Luminex Units/mL. The assay was fully characterized in terms of specificity, precision, linearity, and repeatability. This immunoassay demonstrates performance suitable for future clinical trials, as well as to perform sero-epidemiological studies to gain insights into naturally occurring immunity, potentially contributing to the establishment of a serological threshold of risk reduction against .
是全球医院感染、新生儿败血症和儿童死亡率的主要原因。抗生素耐药菌株的急剧增加对人类构成了紧迫威胁,世界卫生组织(WHO)已将其列为关键优先抗微生物耐药(AMR)病原体。近期针对开发疫苗的进展凸显了缺乏评估免疫原性的标准化检测方法,这使得正在研发的不同疫苗之间的比较以及降低风险血清学阈值(SToRR)的确定变得复杂。在此,我们描述了一种十重多重检测方法的开发,用于测量针对荚膜多糖(K2、K25、K102、K149)、O抗原(O1v1、O1v2、O2v1、O2v2和O5)以及一种保守蛋白(MrkA)的IgG。通过汇集自然暴露受试者的人血清建立标准曲线,然后以相对Luminex单位/毫升进行校准。该检测方法在特异性、精密度、线性和可重复性方面进行了全面表征。这种免疫检测方法显示出适用于未来临床试验的性能,以及进行血清流行病学研究以深入了解自然产生的免疫力,这可能有助于建立针对的降低风险血清学阈值。